REPLY: Value Based Medicine Is Born, the Platform Created by Laife Reply for IEO That Makes Patient Care Increasingly Personalised and Appropriate
22 Avril 2024 - 9:30AM
Business Wire
Laife Reply, a company within the Reply Group focused on using
AI, Big Data and Machine Learning to innovate preventive healthcare
and treatment processes has developed, in collaboration with IEO
(European Institute of Oncology), the Value Based Medicine (VBM), a
web platform to support the patient care cycle.
The platform's objective is to use clinical information to
predict, through statistical and artificial intelligence models,
the outcomes of therapeutic and interventional treatment options,
prioritising the patient's quality of life, both in terms of health
and psychophysical well-being.
The project by Laife Reply and IEO embodies the principles of
value-based medicine. It implements, in a software platform,
methods for measuring the improvement of patient care outcomes.
These methods are derived not only from the analysis of clinical
data produced during the treatment of the pathology, but also from
the analysis of the patient's quality of life resulting from it.
The goal of value-based medicine is to create more "value" for
patients, enabling them to have a better quality of life, while at
the same time ensuring the appropriateness of care.
Among the main distinctive features of the platform is the
ability to determine the probability of post-operative
complications through artificial intelligence models, monitoring
the patient's health status through periodic surveys, and
supporting the patient by showing them the subsequent checkpoints
of their care pathway. The AI tools adopted allow dynamically
defining predictive models for each patient, effectively creating a
personalised value measurement pathway.
The platform was first implemented with urological surgery data
starting in 2019 and subsequently applied to breast and thoracic
surgery. The Institute's goal is to extend it to all surgeries so
that VBM can become a "general purpose" platform.
Since September 2023, IEO has started the certification process
of the platform as a medical device. In addition, in November 2023,
VBM received the Agenas (National Agency for Regional Health
Services) and Sics (Italian Society of Scientific and Health
Communication) Award for Innovation in Digital Health. Thanks to
ongoing developments, supported by the IEO working group and Laife
Reply's technological expertise, the project is significantly
contributing to improving access to healthcare services and the
quality of care, ensuring citizens receive personalised and
attentive care, delivered with increasing efficiency. Tangibility,
sustainability, and replicability are the main qualities recognised
in the platform that have led to its recognition.
Finally, it is essential for the digital transformation
undertaken by the Institute that the VBM platform integrates with
the Clinical Data Platform, CDP, the IEO Datalake of clinical data
and real-world data, also developed by Laife Reply, which
represents for IEO the interoperable digital ecosystem for the
care, prevention, and research of oncological pathologies.
Reply
Reply [EXM, STAR: REY] specialises in the design and
implementation of solutions based on new communication channels and
digital media. Reply is a network of highly specialised companies
supporting key European industrial groups operating in the telecom
and media, industry and services, banking, insurance and public
administration sectors in the definition and development of
business models enabled for the new paradigms of big data, cloud
computing, digital media and the Internet of Things. Reply services
include: Consulting, System Integration and Digital Services.
www.reply.com
Laife Reply
Laife Reply, a company within the Reply group, operates in the
Health, Welfare, and Pharma sectors and develops artificial
intelligence solutions ranging from Medical Imaging, Drug
Discovery, Digital Therapeutics to Natural Language Processing for
the analysis of unstructured data.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240422166626/en/
Press: Reply Fabio Zappelli f.zappelli@reply.com
Tel. +390117711594 Irene Caia i.caia@reply.com Tel. +39 02
535761
Reply (BIT:REY)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Reply (BIT:REY)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024